Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amy V. Kapp"'
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Autor:
Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura
Publikováno v:
Cancer Research. 80:OT1-08
Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanis
Autor:
Farhad Sedarati, Wolfgang Dummer, Piotr Leszczyński, James Taylor, Joseph E Huffstutter, Dalia Moawad, Joy Schechtman, Marek Brzosko, Amy V Kapp, Rebecca Sudlow
Publikováno v:
International Journal of Clinical Rheumatology. 6:689-696
Aim: To test the hypothesis that a therapeutic dose of ocrelizumab (200 mg × 2), can be administered as a single-infusion (400 mg × 1) to achieve clinical efficacy and safety in patients with active rheumatoid arthritis. Patients & methods: Three h
Autor:
Catherine Littman, Andrea Pirzkall, David S. Shames, Andrés Cervantes, George R. Blumenschein, Sandra Sanabria Bohorquez, Amy V. Kapp, Dejan Juric, Rodrigo Dienstmann, Wells A. Messersmith, Lukas C. Amler, X. Wang, José Baselga, Antonio Jimeno, Antonio Calles, Cecilia Leddy, Elicia Penuel, Manuel Hidalgo, Desamparados Roda, Josep Tabernero
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(11)
Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A.
Autor:
Amy V. Kapp, Rodrigo Dienstmann, José Baselga, Antonio Jimeno, Desamparados Roda, Josep Tabernero, Antonio Calles, Manuel Hidalgo, Dejan Juric, G. Scott Chandler, Andrés Cervantes, Wells A. Messersmith, Andrea Pirzkall, Yan Xin, George R. Blumenschein
Publikováno v:
Cancer Research. 72:CT-08
Background Dysregulated human epidermal growth factor receptor tyrosine kinase (HER RTK) signaling is an important driver of tumor growth, metastasis, and survival. Extensive HER RTK co-expression and heterodimerization suggest that simultaneous bloc